Hints and tips:
Related Special Reports
...Swiss company Roche acquired obesity drug developer Carmot Therapeutics for $3.1bn last month, while AstraZeneca signed a $2bn licensing agreement with Eccogene, a Chinese maker of an oral obesity drug in...
...This month, Roche agreed to buy Carmot Therapeutics, a US start-up with potential GLP-1 drugs, for up to $3.1bn....
...The New York-based pharma group has acquired four companies — Arena, ReViral, Biohaven and Global Blood Therapeutics — that it expects will contribute about $10bn in revenues in 2030....
...Roche is to acquire Carmot Therapeutics for up to $3.1bn, in the industry’s latest significant investment in the booming obesity treatment market....
...It is acquiring US-based obesity drugs developer Carmot Therapeutics for up to $3.1bn. It is the second bolt-on acquisition by Roche’s new chief executive Thomas Schinecker in less than two months....
...AstraZeneca has signed a licensing agreement with Chinese company Eccogene, which is developing a weight-loss pill, while Swiss pharma group Roche bought obesity drug developer Carmot Therapeutics for $2.7bn...
...Roche has agreed to buy anti-obesity drug developer Carmot Therapeutics for up to $3.1bn, as the Swiss pharmaceutical group joins the industry’s charge into the fast-growing market for weight loss treatments...
...Consider how Roche spent its cash. It acquired obesity drug developer Carmot Therapeutics for $2.7bn....
...In December, BMS announced a $14bn deal for Karuna Therapeutics which owns the schizophrenia drug KarXT....
...Roche and AstraZeneca have already struck deals to buy or license early stage weight-loss drugs....
...Roche will pay $7.1bn upfront and a near-term milestone payment of $150mn. Pfizer will keep the commercialisation rights outside the US and Japan....
...California’s Carmot Therapeutics is working on GLP-1 and other analogues that promise to be relatively well-tolerated. Roche recently agreed to buy the company for up to $3bn....
...Arcus Biosciences soared 25 per cent and iTeos Therapeutics jumped 28 per cent in pre-market trading....
...Last month, Swiss pharmaceutical company Roche agreed an up to $3.1bn takeover of obesity drug developer Carmot Therapeutics....
...“Until it is further scrutinised, it is difficult to predict the value of this new antibiotic against serious Gram-negative infections as a singular therapeutic,” said Walsh, who was not involved in the...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Such software is part of the new and growing sector of “collaborative work management”, where providers include Asana and Monday.com....
...molnupiravir or Paxlovid will [still] be effective, now that most people have been either vaccinated or infected,” said Andy Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics...
...to rescue Farfetch Regulators even out the antitrust score Global regulators had been on a losing streak lately, with back-to-back losses including Amgen’s $28bn takeover of fellow drugmaker Horizon Therapeutics...
...The drugmakers Pfizer and Roche said they are piloting use of rFC at some of their facilities....
...Monday’s acquisition by Novartis of Seattle-based biotech firm Chinook Therapeutics for up to $3.5bn is a case in point....
...The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to...
...Andrew Hill, a senior visiting research fellow at Liverpool university’s pharmacology and therapeutics department, said the drug also had potential side effects for pregnant women....
...Massachusetts-based Luminopia, which creates therapeutic visual stimuli, raised $16mn in late June....
...One recent study found that fewer than a third of new drugs approved in Europe and the US between 2007 and 2017 were rated of “high therapeutic value”....
International Edition